期刊文献+

经皮冠状动脉介入治疗顽固性心力衰竭的临床疗效 被引量:3

下载PDF
导出
摘要 目的:研究经皮冠状动脉介入治疗(PCI)缺血性心肌病(ICM)顽固性心力衰竭的临床疗效及安全性。方法:选取2016年9月至2018年6月郏县第二人民医院收治的ICM顽固性心力衰竭患者86例,按随机数字表法分为观察组(43例)和对照组(43例),对照组予常规药物治疗,在此基础上观察组予PCI。比较两组患者临床疗效,不良反应情况及治疗前后左心室舒张末内径(LVEDD)、左心室射血分数(LVEF)、左心室收缩末内径(LVESD)。结果:观察组不良事件发生率均显著低于对照组,差异具有统计学意义(P<0.05);观察组临床总有效率为97.67%显著高于对照组的79.07%,差异具有统计学意义(P<0.05);治疗后两组患者LVEDD、LVEF和LVESD均有所改善,且观察组改善优于对照组,差异具有统计学意义(P<0.05)。结论:对ICM顽固性心力衰竭患者行PCI治疗可显著提升临床疗效,降低不良事件的发生机率,进一步提升病患心功能恢复。
作者 周军红
出处 《深圳中西医结合杂志》 2020年第9期118-120,共3页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献5

二级参考文献39

  • 1韩雅玲,臧红云,王冬梅,荆全民,王守力,王祖禄.冠状动脉介入治疗联合心脏再同步化治疗缺血性心肌病顽固性心力衰竭[J].中华心血管病杂志,2005,33(1):17-21. 被引量:30
  • 22016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association ( HFA ) of the ESC [ J ]. Eur J Heart Fail, 2016 May 20.
  • 3John JV, Milton P, Akshay SD, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial ( PARADIGM-HF ) [ J ]. Eur J Heart Fail, 2013, 15 ( 9 ) : 1062-1073.[ Epub ahead of print].
  • 42016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task [ J ]. Circulation, 2016 May 22. [ Epub ahead of print].
  • 5Maisel A, Mueller C, Adams K, et al. State of the art : using natriuretic peptide levels in clinical practice [ J ]. Eur J Heart Fail, 2008, 10 (9) : 824-839.
  • 6Ewald B, Ewald D, Thakkinstian A, et al. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction [ J ]. Intern Med J, 2008, 38 (2) : 101-113.
  • 7Ponikowski P, Jankowska EA. Pathogenesis and clinical presentation of acute heart failure [ J]. Rev Esp Cardiol (Engl Ed) , 2015, 68 (4) : 331-337.
  • 8Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure [J]. J Am Coil Cardiol, 2003, 41 (10): 1797- 1804.
  • 9Stevenson LW. Design of therapy for advanced heart failure [ J ]. Eur J Heart Fail, 2005, 7 ( 3 ) : 323-331.
  • 10Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure : an ADHERE ( Acute Decompensated Heart Failure National Registry) analysis [ J]. J Am Coll Cardiol, 2008, 52 (7) : 534-540.

共引文献155

同被引文献36

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部